ATYR, SGMO, and AQST News: FDA Meeting, Fabry Trial Success, Anaphylaxis Drug Rejection

[Para 1: The Lead] Advanced Therapies, Inc. (ATYR) is scheduled to meet with the U.S. Food and Drug Administration on February 28, 2026, to discuss its lead gene therapy candidate for spinal muscular atrophy. The meeting could impact the company's regulatory timeline and stock price. [Para 2: Supporting Details & Context] San Graphia Pharmaceuticals (SGMO) reported positive top-line results from its Phase 3 Fabry disease trial, with the primary endpoint showing statistically significant improvement. The company plans to discuss potential regulatory filings in the first quarter of 2026. Advanced Therapies, Inc. (AQST) faced a setback as its anaphylaxis treatment, AT-101, was rejected by the FDA for insufficient evidence of clinical benefit. The rejection is expected to delay the company's pipeline advancements and negatively impact its stock performance.